The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Zacks.com on MSN20h
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority TagSanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...
When caught early, skin cancer is highly treatable. Find out if there is a free skin cancer check near you by using the map below. Clicking on your state will show you the scheduled free skin cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback